Vaccines against the coronavirus type 2 causing severe acute respiratory syndrome Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) have been created in a short period of time due to the rapid spread of the virus. These vaccines use different and sometimes innovative technologies, such as the use of ribonucleic acid (RNA), or a non-replicating viral vector. Efficacy ranging from 70-90% in the first weeks after the second injection of these vaccines has been reported, with side effects whose causality remains to be determined.
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Study Type
OBSERVATIONAL
Enrollment
10,000
Centre National de Depistage - Espace Leo Ferre
Monaco, Monaco
RECRUITINGCovid-19 Neutralizing Antibodies Measurment
Inform any individual who has been infected with or vaccinated against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) have about their level of immune protection, through a bi-annual follow-up
Time frame: 24-month period
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.